Advances in PET Imaging of Sarcoidosis

Research output: Contribution to journalReview article

Abstract

Purpose of Review: The purpose of this paper is to provide an updated review of recent advances in protocols for positron emission tomography (PET) or PET/computed tomography (PET/CT) imaging in patients with sarcoidosis. Recent Findings: There has been more research focused on developing newer and improved PET imaging modalities to diagnose and follow-up cardiac sarcoidosis (CS). Fluorine-18-fluorodeoxyglucose ( 18 F- FDG)-PET are widely used to diagnose CS, with or without concurrent rest nuclear myocardial perfusion study. There have been various patient preparation strategies for FDG PET/CT in CS. Interpretation criteria for cardiac FDG PET/CT in diagnosing CS also varies. There are emerging data utilizing new PET radiotracers (i.e., 68 Ga-DOTATATE, 18 F-Flurpiridaz) and PET/MRI imaging for CS diagnosis. Summary: Based on published imaging data, patient preparation with a 72-h high-fat, high-protein, and very-low-carbohydrate diet protocol generates the most promising results in suppression of physiological myocardial FDG uptake in cardiac PET/CT. The “focal-on-diffuse uptake” pattern on myocardial uptake is not convincing and should not be interpreted as active CS. Nuclear myocardial perfusion test might not be needed to diagnose CS if optimal suppression of myocardial background uptake of FDG is achieved. FDG PET/MRI with optimal patient preparation may increase diagnostic confidence. More data will be needed for new tracers to be used for CS diagnosis.

Original languageEnglish (US)
Article number10
JournalCurrent Cardiovascular Imaging Reports
Volume12
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Sarcoidosis
Positron-Emission Tomography
Perfusion
Carbohydrate-Restricted Diet
Fluorodeoxyglucose F18
Fats
Research

Keywords

  • Cardiac sarcoidosis
  • PET; PET/CT
  • Sarcoidosis

ASJC Scopus subject areas

  • Histology
  • Applied Microbiology and Biotechnology
  • Cell Biology

Cite this

Advances in PET Imaging of Sarcoidosis. / Lu, Yang; Macapinlac, Homer A.

In: Current Cardiovascular Imaging Reports, Vol. 12, No. 3, 10, 01.03.2019.

Research output: Contribution to journalReview article

@article{558eb20a9a2a41ccb9ad9ae3353142a1,
title = "Advances in PET Imaging of Sarcoidosis",
abstract = "Purpose of Review: The purpose of this paper is to provide an updated review of recent advances in protocols for positron emission tomography (PET) or PET/computed tomography (PET/CT) imaging in patients with sarcoidosis. Recent Findings: There has been more research focused on developing newer and improved PET imaging modalities to diagnose and follow-up cardiac sarcoidosis (CS). Fluorine-18-fluorodeoxyglucose ( 18 F- FDG)-PET are widely used to diagnose CS, with or without concurrent rest nuclear myocardial perfusion study. There have been various patient preparation strategies for FDG PET/CT in CS. Interpretation criteria for cardiac FDG PET/CT in diagnosing CS also varies. There are emerging data utilizing new PET radiotracers (i.e., 68 Ga-DOTATATE, 18 F-Flurpiridaz) and PET/MRI imaging for CS diagnosis. Summary: Based on published imaging data, patient preparation with a 72-h high-fat, high-protein, and very-low-carbohydrate diet protocol generates the most promising results in suppression of physiological myocardial FDG uptake in cardiac PET/CT. The “focal-on-diffuse uptake” pattern on myocardial uptake is not convincing and should not be interpreted as active CS. Nuclear myocardial perfusion test might not be needed to diagnose CS if optimal suppression of myocardial background uptake of FDG is achieved. FDG PET/MRI with optimal patient preparation may increase diagnostic confidence. More data will be needed for new tracers to be used for CS diagnosis.",
keywords = "Cardiac sarcoidosis, PET; PET/CT, Sarcoidosis",
author = "Yang Lu and Macapinlac, {Homer A}",
year = "2019",
month = "3",
day = "1",
doi = "10.1007/s12410-019-9485-5",
language = "English (US)",
volume = "12",
journal = "Current Cardiovascular Imaging Reports",
issn = "1941-9066",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Advances in PET Imaging of Sarcoidosis

AU - Lu, Yang

AU - Macapinlac, Homer A

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Purpose of Review: The purpose of this paper is to provide an updated review of recent advances in protocols for positron emission tomography (PET) or PET/computed tomography (PET/CT) imaging in patients with sarcoidosis. Recent Findings: There has been more research focused on developing newer and improved PET imaging modalities to diagnose and follow-up cardiac sarcoidosis (CS). Fluorine-18-fluorodeoxyglucose ( 18 F- FDG)-PET are widely used to diagnose CS, with or without concurrent rest nuclear myocardial perfusion study. There have been various patient preparation strategies for FDG PET/CT in CS. Interpretation criteria for cardiac FDG PET/CT in diagnosing CS also varies. There are emerging data utilizing new PET radiotracers (i.e., 68 Ga-DOTATATE, 18 F-Flurpiridaz) and PET/MRI imaging for CS diagnosis. Summary: Based on published imaging data, patient preparation with a 72-h high-fat, high-protein, and very-low-carbohydrate diet protocol generates the most promising results in suppression of physiological myocardial FDG uptake in cardiac PET/CT. The “focal-on-diffuse uptake” pattern on myocardial uptake is not convincing and should not be interpreted as active CS. Nuclear myocardial perfusion test might not be needed to diagnose CS if optimal suppression of myocardial background uptake of FDG is achieved. FDG PET/MRI with optimal patient preparation may increase diagnostic confidence. More data will be needed for new tracers to be used for CS diagnosis.

AB - Purpose of Review: The purpose of this paper is to provide an updated review of recent advances in protocols for positron emission tomography (PET) or PET/computed tomography (PET/CT) imaging in patients with sarcoidosis. Recent Findings: There has been more research focused on developing newer and improved PET imaging modalities to diagnose and follow-up cardiac sarcoidosis (CS). Fluorine-18-fluorodeoxyglucose ( 18 F- FDG)-PET are widely used to diagnose CS, with or without concurrent rest nuclear myocardial perfusion study. There have been various patient preparation strategies for FDG PET/CT in CS. Interpretation criteria for cardiac FDG PET/CT in diagnosing CS also varies. There are emerging data utilizing new PET radiotracers (i.e., 68 Ga-DOTATATE, 18 F-Flurpiridaz) and PET/MRI imaging for CS diagnosis. Summary: Based on published imaging data, patient preparation with a 72-h high-fat, high-protein, and very-low-carbohydrate diet protocol generates the most promising results in suppression of physiological myocardial FDG uptake in cardiac PET/CT. The “focal-on-diffuse uptake” pattern on myocardial uptake is not convincing and should not be interpreted as active CS. Nuclear myocardial perfusion test might not be needed to diagnose CS if optimal suppression of myocardial background uptake of FDG is achieved. FDG PET/MRI with optimal patient preparation may increase diagnostic confidence. More data will be needed for new tracers to be used for CS diagnosis.

KW - Cardiac sarcoidosis

KW - PET; PET/CT

KW - Sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=85061649776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061649776&partnerID=8YFLogxK

U2 - 10.1007/s12410-019-9485-5

DO - 10.1007/s12410-019-9485-5

M3 - Review article

VL - 12

JO - Current Cardiovascular Imaging Reports

JF - Current Cardiovascular Imaging Reports

SN - 1941-9066

IS - 3

M1 - 10

ER -